相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia et al.
GASTROENTEROLOGY (2017)
From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers
Ioannis D. Kyrochristos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine
Dimitrios H. Roukos
DRUG DISCOVERY TODAY (2017)
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer
Akihiro Fujimoto et al.
NATURE GENETICS (2016)
Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis
Parissa Tabrizian et al.
ANNALS OF SURGERY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix et al.
LANCET ONCOLOGY (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Peter Eirew et al.
NATURE (2015)
Genomic Portrait of Resectable Hepatocellular Carcinomas: Implications of RB1 and FGF19 Aberrations for Patient Stratification
Sung-Min Ahn et al.
HEPATOLOGY (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix et al.
EUROPEAN JOURNAL OF CANCER (2013)
Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design
Maria Reig et al.
HEPATOLOGY (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Daniel Hofmann et al.
TRIALS (2013)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers
Hauke Lang et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2007)
分享论文
